Shionogi

Japan - OsakaBiotechnology2 H-1B visas (FY2023)

Focus: Shionogi is a Japanese pharmaceutical company founded in 1878 with a legacy focus on infectious diseases and small-molecule therapeutics. Currently operating at a smaller scale with 44 active job openings, the company is heavily dependent on its peak-stage antibiotic FETROJA.

Infectious Diseases

Profile data last refreshed 7h ago · AI intelligence enriched 2w ago

Open Jobs

36+34 this month

Hot — 81 jobs added in 30d

Net +34 (81 new, 47 removed). Aggressive expansion phase.

Should You Work at Shionogi?

AI assessment

Shionogi offers a specialized niche in antibiotic development and infectious disease with a proven commercial asset, but extreme product concentration and commercially-focused hiring make it a higher-risk career move unless you seek infectious disease specialization.

Why Work Here

Leadership role in infectious disease innovation with FETROJA (cefiderocol), a novel siderophore cephalosporin addressing antibiotic-resistant gram-negative infections at peak commercial stage

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

FETROJA

Complicated urinary tract infections (cUTIs), including pyelonephritis caused by gram-negative pathogens

$4M Part D

Peak

Help build intelligence for Shionogi

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline spanning HIV (dolutegravir), influenza (baloxavir marboxil), oncology (durvalumab, S-588410), and specialty therapeutics (naldemedine, ospemifene) with 30 active programs

Japanese pharmaceutical heritage (founded 1878) with global commercial ambitions evidenced by active U.S. hiring and FDA approval infrastructure

Watch Out For

Extreme revenue concentration risk: 100% of revenue from single product (FETROJA) creates business vulnerability if sales decline or patent protection erodes before 2035
Hiring heavily skewed toward commercial roles (38 of 44 openings) rather than R&D, suggesting limited scientific career depth and focus on maximizing FETROJA sales rather than pipeline advancement
Limited disclosed financial data (no revenue, R&D spend, or cash position reported) and minimal H1B sponsorship (2 approvals in 2023) reduce visibility and visa flexibility

Generated by Claude from Shionogi's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Shionogi's sole revenue driver and a novel siderophore cephalosporin with 13 years of patent protection remaining, currently in peak commercial phase.

COGNEX

Alzheimer's disease (historical)

LOE Approaching

Legacy product with approaching loss of exclusivity; no active development or significant commercial relevance.

DORIBAX

Intra-abdominal infections, urinary tract infections, pneumonia

LOE Approaching

Carbapenem antibiotic now facing LOE; part of legacy portfolio with limited competitive positioning.

RYBIX ODT

Pain, low back pain, osteoarthritis

LOE Approaching

Opioid analgesic with approaching exclusivity loss and declining relevance in pain management market.

Products & Portfolio (1)

7 discontinued, 0 duplicate formulations not shown

Key Products by Revenue

FETROJA

cefiderocol sulfate tosylate

Pipeline & Clinical Trials

Cefiderocol

Gram-Negative Infection

N/A

Clinical Trials (1)

NCT05789199Use of Cefiderocol in the Management of Gram-Negative Infections

N/A

A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Tim

RSV Infections

N/A

Clinical Trials (1)

NCT06746051A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants

N/A

Cefiderocol

Bacterial Infections

N/A

Clinical Trials (1)

NCT03780140Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

N/A

Baloxavir Marboxil

Healthy Volunteer

N/A

NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group

Autism Spectrum Disorder

N/A

Clinical Trials (1)

NCT06772324An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders

N/A

Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

Vulvovaginal Atrophy

N/A

Clinical Trials (1)

NCT04607707Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

N/A

Cetrorelix

Premenopause

N/A

Clinical Trials (1)

NCT00628121Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer

N/A

Ensitrelvir

Healthy Adult Female Participants

Phase 1

Clinical Trials (1)

NCT06775730A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

Phase 1

GSK1349572

Healthy Subjects

Phase 1

GSK1349572 250 mg

Healthy Subjects

Phase 1

BPN14770

Renal Impairment

Phase 1

Clinical Trials (1)

NCT07012005Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

Phase 1

S-892216-PO

Renal Impairment

Phase 1

Clinical Trials (1)

NCT07217886A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

Phase 1

GSK1349572

Infection, Human Immunodeficiency Virus

Phase 1

GSK1349572

Infections, Human Immunodeficiency Virus and Tuberculosis

Phase 1

Cefiderocol/Xeruborbactam

Bacterial Infections

Phase 1

Xeruborbactam Oral Prodrug

Bacterial Infections

Phase 1

BPN14770

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT07018492Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

Phase 1

GSK1349572

Infection, Human Immunodeficiency Virus

Phase 1

S-707106

Type 2 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01154348Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus

Phase 1

DTG

Infection, Human Immunodeficiency Virus

Phase 1

S-217622

Renal Impairment

Phase 1

Clinical Trials (1)

NCT05363215A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

Phase 1

GSK1349572

Healthy Volunteer